A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
Price : $35 *
At a glance
- Drugs MK 8876 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 05 Jan 2016 According to ClinicalTrials.gov record,Number of treatments arms has been changed from 10 to 3.
- 27 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.